Anthropic has warned that recursive-self-improving AI could be on the horizon, but the truth is the company is more ...

DataHub's Context Intelligence mines validated SQL query history to build a semantic index for AI agents. At Miro, agents hit a 65% error rate without it.

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.